299 related articles for article (PubMed ID: 20228816)
1. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
McMillin DW; Delmore J; Weisberg E; Negri JM; Geer DC; Klippel S; Mitsiades N; Schlossman RL; Munshi NC; Kung AL; Griffin JD; Richardson PG; Anderson KC; Mitsiades CS
Nat Med; 2010 Apr; 16(4):483-9. PubMed ID: 20228816
[TBL] [Abstract][Full Text] [Related]
2. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells.
Misund K; Baranowska KA; Holien T; Rampa C; Klein DC; Børset M; Waage A; Sundan A
J Biomol Screen; 2013 Jul; 18(6):637-46. PubMed ID: 23446700
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
4. Cell-based bioluminescence screening assays.
Amante RJ; Badr CE
Methods Mol Biol; 2014; 1098():185-95. PubMed ID: 24166378
[TBL] [Abstract][Full Text] [Related]
5. Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation.
Zhang GJ; Chen TB; Bednar B; Connolly BM; Hargreaves R; Sur C; Williams DL
Neoplasia; 2007 Aug; 9(8):652-61. PubMed ID: 17786184
[TBL] [Abstract][Full Text] [Related]
6. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.
McMillin DW; Delmore J; Negri JM; Vanneman M; Koyama S; Schlossman RL; Munshi NC; Laubach J; Richardson PG; Dranoff G; Anderson KC; Mitsiades CS
Blood; 2012 Apr; 119(15):e131-8. PubMed ID: 22289890
[TBL] [Abstract][Full Text] [Related]
7. A screening platform for glioma growth and invasion using bioluminescence imaging. Laboratory investigation.
Zhao H; Tang C; Cui K; Ang BT; Wong ST
J Neurosurg; 2009 Aug; 111(2):238-46. PubMed ID: 19199503
[TBL] [Abstract][Full Text] [Related]
8. Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs.
Campana D; Manabe A; Evans WE
Leukemia; 1993 Mar; 7(3):482-8. PubMed ID: 7680404
[TBL] [Abstract][Full Text] [Related]
9. Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells.
Kuo CH; Lu YC; Tseng YS; Shi CS; Chen SH; Chen PT; Wu FL; Chang YP; Lee YR
Breast Cancer; 2014 May; 21(3):358-69. PubMed ID: 22926505
[TBL] [Abstract][Full Text] [Related]
10. The critical role of the bone marrow stromal microenvironment for the development of drug screening platforms in leukemia.
Panting RG; Kotecha RS; Cheung LC
Exp Hematol; 2024 May; 133():104212. PubMed ID: 38552942
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells.
Rhedin AS; Tidefelt U; Jönsson K; Lundin A; Paul C
Leuk Res; 1993 Mar; 17(3):271-6. PubMed ID: 7680736
[TBL] [Abstract][Full Text] [Related]
12. Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.
Tsai HJ; Kobayashi S; Izawa K; Ishida T; Watanabe T; Umezawa K; Lin SF; Tojo A
Cancer Sci; 2011 Nov; 102(11):2014-21. PubMed ID: 21777350
[TBL] [Abstract][Full Text] [Related]
13. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Teicher BA
Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
[TBL] [Abstract][Full Text] [Related]
14. Luminescence applications for chemotherapeutic drug development.
Andreotti PE; Caceres G; Zamkina R; Dauphinée M
Recent Results Cancer Res; 2003; 161():3-12. PubMed ID: 12528794
[TBL] [Abstract][Full Text] [Related]
15. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
[TBL] [Abstract][Full Text] [Related]
16. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Kumar S; Raje N; Hideshima T; Ishitsuka K; Roccaro A; Shiraishi N; Hamasaki M; Yasui H; Munshi NC; Richardson P; Figg WD; Anderson KC
Leukemia; 2005 Jul; 19(7):1253-61. PubMed ID: 15858615
[TBL] [Abstract][Full Text] [Related]
17. In vitro drug resistance versus chemosensitivity: two sides of different coins.
Fruehauf JP; Alberts DS
J Clin Oncol; 2005 May; 23(15):3641-3; author reply 3646-8. PubMed ID: 15908686
[No Abstract] [Full Text] [Related]
18. [A new chemosensitivity test for cancer cells by measuring intracellular ATP content].
Nogaki M; Ichihashi H
Nihon Geka Gakkai Zasshi; 1988 Dec; 89(12):1950-6. PubMed ID: 3231205
[TBL] [Abstract][Full Text] [Related]
19. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
20. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
Azab F; Vali S; Abraham J; Potter N; Muz B; de la Puente P; Fiala M; Paasch J; Sultana Z; Tyagi A; Abbasi T; Vij R; Azab AK
Br J Haematol; 2014 Apr; 165(1):89-101. PubMed ID: 24405121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
